About Sarepta Therapeutics
Sarepta Therapeutics (NASDAQ:SRPT) is a biotechnology firm that specializes in the discovery and development of precision genetic medicines. The company's primary focus is on treatments for rare diseases, especially those affecting the muscular and central nervous systems. Sarepta Therapeutics is known for its groundbreaking work in Duchenne muscular dystrophy (DMD) therapies, aiming to address the underlying genetic causes of this and other diseases to improve patients' lives significantly. As of now, the company is actively involved in various stages of research, clinical trials, and the development of new drug candidates, with the objective of expanding its portfolio of therapies and making a meaningful impact in areas with unmet medical needs.
Snapshot
Operations
Products and/or services of Sarepta Therapeutics
- Exondys 51, a treatment for Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation amenable to exon 51 skipping.
- Vyondys 53, designed for the treatment of DMD in patients who have a specific genetic mutation that can benefit from exon 53 skipping.
- Amondys 45, an antisense oligonucleotide for DMD patients with a mutation amenable to exon 45 skipping.
- Gene therapy program to address genetic mutations in DMD, aiming to deliver a functional dystrophin gene to muscle cells.
- RNA platform targeting the precise modulation of protein expression for various genetic disorders, enabling potential treatments for multiple diseases.
- Casimersen, in development for the treatment of DMD among patients with genetic mutations amenable to exon 45 skipping, further expanding the company'??s DMD exon-skipping portfolio.
Sarepta Therapeutics executive team
- Mr. Douglas S. Ingram Esq., J.D.CEO & Director
- Mr. Ian Michael EstepanPresident & COO
- Dr. Louise R. Rodino-Klapac Ph.D.President of Research & Development and Technical Operations
- Ryan H. WongExecutive VP & CFO
- Rachael Potter Ph.D.Chief Scientific Officer
- Tamara ThorntonDirector of Finance, Treasury & Investor Relations
- Ms. Cristin L. Rothfuss J.D.Executive VP, Chief General Counsel & Corporate Secretary
- Ms. Alison NasisiExecutive VP & Chief People Officer
- Dr. Diane L. Berry Ph.D.Executive VP and Chief of Global Policy & Advocacy Officer
- Patrick Moss Pharm.D.Executive VP & Chief Commercial Officer